A new “hope” for diabetics in Tunisia
Tunisian laboratories said that they are manufacturing the first biological alternative to insulin in Tunisia to treat type 1 diabetes, noting that this locally manufactured biological drug opens new horizons for patients, due to its current availability and reasonable price.
The pharmacist in charge of the biotechnology project at Medis laboratories, Nadia Ben Said, explained that the price of the drug is 17 Tunisian dinars ($5.5), meaning that its cost is 40% less than the available imported similar drugs.
The drug, whose trade name is "Glargine", was developed over a period of 10 years.
Nadia Ben Said indicated that it was completely manufactured and quality controlled in Tunisia.
She added, "According to recent statistics, the percentage of diabetic patients in Tunisia is about 21% of the population. These patients' lives will change with this vital alternative because it is locally made, and it will be more available, as we have produced a reserve to secure our needs for a period of up to three months, to avoid shortage problems." The supplied medicines that we have seen recently.”
The company is now working on developing another treatment for type 2 diabetes.
Follow our latest local and sports news and the latest political and economic developments via Google news